OncoMatch/Clinical Trials/NCT06418477
Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD
Is NCT06418477 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Dara-CyBorD for monoclonal gammopathy of renal significance.
Treatment: Dara-CyBorD — This is an open-label, multicenter, Phase 2 study in subjects with newly diagnosed monoclonal immunoglobulin deposition disease treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anti-plasma cell treatment
Exception: ≤160 mg dexamethasone (or equivalent corticosteroid)
Prior therapy for MIDD, with the exception of equal or less than 160 mg dexamethasone (or equivalent corticosteroid)
Lab requirements
Blood counts
Neu≥ 1.0*10^9/L, HGB ≥70g/L, PLT ≥ 50*10^9/L
Liver function
Total bilirubin (TBil) ≤3×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN
Neu≥ 1.0*10^9/L, HGB ≥70g/L, PLT ≥ 50*10^9/L. Total bilirubin (TBil) ≤3×upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3.0×ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify